Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

PHASE3CompletedINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

February 3, 2023

Study Completion Date

February 8, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

tapinarof cream, 1%

applied topically once daily

DRUG

vehicle cream

applied topically once daily

Trial Locations (62)

11203

Dermanvant Investigative Site, Brooklyn

13601

Dermavant Investigative Site, Watertown

20850

Dermavant Investigative Site, Rockville

28277

Dermavant Investigative Site, Charlotte

29303

Dermavant Investigative Site, Spartanburg

29420

Dermavant Investigative Site, North Charleston

29621

Dermavant Investigative Site, Anderson

30078

Dermavant Investigative Site, Snellville

32256

Dermavant Investigative Site, Jacksonville

33014

Dermavant Investigative Site, Miami Lakes

33165

Dermavant Investigative Site, Miami

33173

Dermavant Investigative Site, Miami

33428

Dermavant Investigative Site, Boca Raton

33484

Dermavant Investigative Site, Delray Beach

33607

Dermavant Investigative Site, Tampa

35244

Dermavant Investigative Site, Birmingham

38119

Dermavant Investigative Site, Memphis

40241

Dermavant Investigative Site, Louisville

40517

Dermavant Investigative Site, Lexington

44124

Dermavant Investigative Site, Mayfield Heights

45040

Dermavant Investigative Site, Mason

45414

Dermavant Investigative Site, Dayton

47715

Dermavant Investigative Site, Evansville

48202

Dermavant Investigative Site, Detroit

66210

Dermavant Investigative Site, Overland Park

68114

Dermavant Investigative Site, Omaha

68516

Dermavant Investigative Site, Lincoln

70115

Dermavant Investigative Site, New Orleans

70808

Dermavant Investigative Site, Baton Rouge

70809

Dermavant Investigative Site, Baton Rouge

72916

Dermavant Investigative Site, Fort Smith

74114

Dermavant Investigative Site, Tulsa

76051

Dermavant Investigative Site, Grapevine

77004

Dermavant Investigative Site, Houston

77061

Dermavant Investigative Site, Houston

77401

Dermavant Investigative Site, Bellaire

77598

Dermavant Investigative Site, Webster

78213

Dermavant Investigative Site, San Antonio

78620

Dermavant Investigative Site, Dripping Springs

85255

Dermavant Investigative Site, Scottsdale

85260

Dermavant Investigative Site, Scottsdale

89148

Dermavant Investigative Site, Las Vegas

90045

Dermavant Investigative Site, Los Angeles

90404

Dermavant Investigative Site, Santa Monica

90702

Dermavant Investigative Site, Cerritos

90806

Dermavant Investigative Site, Long Beach

92123

Dermavant Investigative Site, San Diego

92647

Dermavant Investigative Site, Huntington Beach

92701

Dermavant Investigative Site, Santa Ana

93534

Dermavant Investigative Site, Lancaster

94115

Dermavant Investigative Site, San Francisco

97210

Dermavant Investigative Site, Portland

97239

Dermavant Investigative Site, Portland

97504

Dermavant Investigative Site, Medford

99202

Dermavant Investigative Site, Spokane

08520

Dermavant Investigative Site, East Windsor

02818

Dermavant Investigative Site, East Greenwich

V3R 6A7

Dermavant Investigative Site, Surrey

L4M 7G1

Dermavant Investigative Site, Barrie

L3P 1X3

Dermavant Investigative Site, Markham

N2J 1C4

Dermavant Investigative Site, Waterloo

N8W 1E6

Dermavant Investigative Site, Windsor

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT05032859 - Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) | Biotech Hunter | Biotech Hunter